Patients with hematological malignancy and infectious complications
Conditions
Interventions
Group 1: Retrospective analysis of routinely collected patient data focusing on colonization with multidrug-resistant organisms, therapeutic safety using therapeutic drug monitoring, and the optimizat
Sponsors
Universitätsklinikum Heidelberg, Innere Medizin V
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Therapy for hematological malignancy at University Hospital Heidelberg and infectious complications
Exclusion criteria
Exclusion criteria: Patients who explicitly object to the storage, processing, or dissemination of their data in anonymized form for the purpose of scientific publication will be excluded
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival | — |
Primary
| Measure | Time frame |
|---|---|
| Top A Antimicrobial Resistance: resistancy rate, colonization rate, blood stream infections with MDR isolates, retrospective analysis 2019-2024, analysis of clinical routine data (doctor's letters, microbiology reports) Top B Therapeutic Drug Monitoring: anti-infective dose, therapy duration, retrospective analysis 2020 -2025, analysis of clinical routine data (doctor's letter, pharmacy data) | — |
Countries
Germany
Contacts
Public ContactElena Busch
Universitätsklinikum Heidelberg, Innere Medizin V
Outcome results
None listed